Summer Street out with bearish commentary on Auxilium

"The sell-off is not surprising to us and we continue to warn investors that the market for Testim will disappear in the foreseeable future," Summer Street says, regarding Auxilium Pharmaceuticals (AUXL) and Wednesday's news regarding an unfavorable district court ruling.

Analyst Bart Classen also warns that when AndroGel goes generic in 2015, "almost no one will pay a premium for branded Testim."

As for the December 6 PDUFA for Xiaflex, Classen is "skeptical that the FDA will approve [it] for Peyronies disease without an Ad Com."

From other sites
Comments (1)
  • libouban
    , contributor
    Comments (143) | Send Message
    The FDA did FDA approve Xiaflex for Peyronies disease.
    I was not impressed by 'Summer Street' lack of argumentation on the subject to start with. From what I've seen so far, it tends to be one-liners, pretty much a thumb up or down.
    6 Dec 2013, 02:00 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs